SOURCE: MarketResearch.com

MarketResearch.com

November 30, 2010 09:08 ET

US Demand for Vaccines to Grow 5.5% Annually Through 2014

ROCKVILLE, MD--(Marketwire - November 30, 2010) - MarketResearch.com has announced the addition of Freedonia Group Inc.'s new report "Vaccines" to their collection of Pharmaceuticals market reports. For more information, visit http://www.marketresearch.com/product/display.asp?ProductID=2800093

Demand for vaccines is forecast to increase 5.5 percent annually to more than $14 billion in 2014. The market has experienced dramatic growth due to increasing routine seasonal influenza immunization and the rising number of preventive and booster vaccines available for adults and adolescents. This growth will be compounded as several new therapeutic vaccines for cancer reach the market, followed in the coming years by biological treatments for Respiratory Syncytial Virus (RSV) and Alzheimer's Disease, and a variety of new vaccines for travel and biodefense.

Pediatric vaccines have been the mainstay of the vaccine market for many years, growing steadily as new products emerged and as a greater number of routine vaccinations were encouraged. Now, a substantial number of primary vaccines and boosters are being recommended for adolescents and older adults, and the market for vaccines has expanded dramatically with the addition of these populations to the target markets for vaccine producers.

Significant growth in the market has been fueled by the introduction of a vaccine for Human Papillomavirus (HPV), recommended for girls and young women and now being considered for males and a wider age range. Seasonal influenza vaccination is also gaining ground and represents a substantial portion of growth in adult vaccines, as new preventive treatments against zoster and meningococcal disease. Also a factor in adult vaccines is the growing use of boosters against tetanus, diphtheria, pertussis and other diseases.

Vaccine demand will be spurred considerably by a number of therapeutic vaccines for cancer that are nearing completion of clinical trials and are poised for FDA approval. There are currently 50 cancer vaccines in phase III or later trials, and the activity surrounding cancer vaccine development is expected to continue at a high pace. Also showing promise are vaccines being developed for RSV, HIV and Alzheimer's Disease. Similarly, a range of vaccines for travel, developing countries and biodefense are in the pipeline, including prophylactics for malaria, hemorrhagic fevers, West Nile virus and plague.

For more information, visit http://www.marketresearch.com/product/display.asp?ProductID=2800093

Contact Information